Altavo’s Artificial Voice is a medical device designed to help voiceless people, for example after laryngectomy or during mechanical ventilation, regain their own, natural sounding voice. The proprietary “silent speech” technology, which has been developed in collaboration with Technical University Dresden, is based on non-invasive radar sensing and the latest neural net architectures.
Investors in the current signficantly oversubscribed round are, in addition to the lead investor OCCIDENT from Munich, Novalis Biotech (Ghent, Belgium), Beteiligungsmanagement Thüringen, and others. In addition, almost all seed investors from the first financing round in December 2021 are participating with a follow-on investment, among them TGFS Technologiegründerfonds Sachsen, High-Tech Gründerfonds (HTGF), Saxonia Systems Holding and TUDAG TU Dresden AG.
The current Series A will finance company growth, product development, the pivotal clinical trial, and internationalization. Altavo’s technology not only promises to become a breakthrough in the rehabilitation of voiceless people, but also opens up entirely new opportunities in silent communication and human-machine interfaces.